Research programme: anti-infectives - Cengent TherapeuticsAlternative Names: ALF inhibitors research programme - Cengent Therapeutics; Zinc metalloprotease inhibitors - Cengent
Latest Information Update: 29 Aug 2007
At a glance
- Originator Cengent Therapeutics
- Class Small molecules
- Mechanism of Action Anthrax toxin inhibitors; Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anthrax